Myriad’s Prolaris Test is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1
New Study Published in JCO Precision Oncology Shows Myriad Genetics‘ Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer
